ASMB (Assembly Biosciences) 1-Year Sharpe Ratio: 1.31 (As of Jul. 04, 2026)


ASMB Assembly Biosciences Inc ASMB
31 GF Score
Price $27.73
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences 1-Year Sharpe Ratio?

Assembly Biosciences ASMB +3.93% 31 1-Year Sharpe Ratio is 1.31 as of Jul. 04, 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-04), Assembly Biosciences's 1-Year Sharpe Ratio is 1.31.

Assembly Biosciences  (NAS:ASMB) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Assembly Biosciences 1-Year Sharpe Ratio Related Terms

ASMB vs CTNM, PRTA, RGNX: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Assembly Biosciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's 1-Year Sharpe Ratio falls into.


ASMB
31GF Score
Assembly Biosciences Inc ASMB
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.31 mean?
Assembly Biosciences (ASMB) has a 1-Year Sharpe Ratio of 1.31 as of Jul. 04, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Assembly Biosciences and its competitors.
Is Assembly Biosciences' 1-Year Sharpe Ratio too high?
Assembly Biosciences' current 1-Year Sharpe Ratio is 1.31. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' 1-Year Sharpe Ratio compare to CTNM and PRTA?
Assembly Biosciences' 1-Year Sharpe Ratio of 1.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Assembly Biosciences and its competitors. Assembly Biosciences's current 1-Year Sharpe Ratio is 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current 1-Year Sharpe Ratio of 1.31. The current 1-Year Sharpe Ratio is 1.31. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current 1-Year Sharpe Ratio is 1.31 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for ASMB

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.73
Price